secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2022-09-29T23:59:59+00:00
Accession:  0001193125-22-254305
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

KURA Oncology amends equity plan to increase shares by 1.46M and grants PSUs to executives
--------------------------------------------------------------------------------

- Board approved amendment to 2014 Equity Incentive Plan to increase shares by 1,459,800, subject to stockholder approval at 2023 Annual Meeting.
- Compensation Committee and Board granted PSUs totaling 1,235,100 shares to five executive officers, contingent on stockholder approval of amendment.
- PSU vesting tied to milestones: FDA NDA approval for ziftomenib in AML, initiation of registration-enabling trial, and Phase 2 start of farnesyl transferase inhibitor combination.
- Executive officers receiving PSUs: CEO Troy Wilson (547,500), CLO Teresa Bair (146,700), CMO Stephen Dale (247,500), CCO Kirsten Flowers (146,700), COO Kathleen Ford (146,700).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312522254305/0001193125-22-254305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312522254305/d388454d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-254305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer